Tevogen Bio Leverages Microsoft Partnership To Deliver Machine Learning Based Target Identification To Address HPV, Advancing TVGN 920
Tevogen Bio Leverages Microsoft Partnership To Deliver Machine Learning Based Target Identification To Address HPV, Advancing TVGN 920
- Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.
- Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process.
- 5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia.
- Tevogen Bio开始了TVGN 920的临床前研究，这标志着其肿瘤治疗产品线的启动。
- Tevogen Bio创建了一个包含HPV基因组中已知蛋白质的数据集，用于识别靶标，从而加快了临床前过程。
- 每年有550万名女性感染16/18型HPV；其中每年有20万名女性被诊断出患有高级别发育不良。
WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (NASDAQ:MSFT), the world's leading AI company.
新泽西州沃伦，2024年11月5日（环球新闻专线）——Tevogen Bio（“Tevogen” 或 “Tevogen Bio Holdings Inc.”）纳斯达克股票代码：TVGN）是一家临床阶段的特种免疫疗法生物技术公司，正在开发用于治疗传染病和癌症的现成的、未经转基因的T细胞疗法。该公司最近宣布，其人工智能项目 Tevogen.AI 已与全球领先的人工智能公司微软（纳斯达克股票代码：MSFT）合作。
Using Microsoft's suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products. The company has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T cell (CTL) targets to choose for a clinical trial for TVGN 920, its first oncology product. Through Tevogen's proprietary ExacTcell technology, where CTLs are trained to detect specific targets and then expanded, the company aims to be prepared to deliver an HPV-specific CTL treatment.
使用微软的高级工具套件，Tevogen Bio正在积极研究HPV的潜在治疗方法，以创建肿瘤产品组合。该公司已经开发了来自HPV基因组的蛋白质数据集，并正在确定细胞毒性T细胞（CTL）靶标，供其首款肿瘤产品TVGN 920的临床试验选择。通过Tevogen的专有ExactCell技术，对CTL进行培训，以检测特定的靶标，然后进行扩展，该公司的目标是为提供人乳头瘤病毒特异性CTL治疗做好准备。